244 - CCS CLINICAL PRACTICE UPDATE ON HYPERTROPHIC CARDIOMYOPATHY

Friday, October 25, 2024

2:00 PM – 3:00 PM PT

Room: 211

Hypertrophic cardiomyopathy (HCM) is a disease of the cardiac muscle affecting 1 in 500 individuals and is associated with significant morbidity and mortality including atrial fibrillation, stroke, heart failure and sudden death. Important progress in HCM has been made in recent years including a better understanding of the genetic basis, improved risk stratification of sudden death, enhanced imaging modalities, and development of new therapies for symptom management. Considering these recent developments, the Canadian Cardiovascular Society recently developed a Clinical Practice Update (CPU) on the Contemporary Management of the Patient with Hypertrophic Cardiomyopathy. This session provides a practical overview of four main sections of this CPU on HCM, namely genetic testing and family screening, sudden cardiac death stratification, cardiac imaging and management of symptomatic obstruction.

The session will consist of two presentations and two case-based debates:
1) Genetic testing and family screening in HCM
2) Imaging HCM: echocardiography, cardiac MRI and beyond
3) Case-based debate: Should my HCM patient get an ICD based on a risk factor or a score ?
4) Case-based debate: Should my patient with obstructive HCM get another drug, an alcohol ablation or myectomy?

Learning Objectives:

At the end of this session participants will be able to:

Recognize the importance of genetic counselling and testing in hypertrophic cardiomyopathy and provide appropriate screening for relatives at risk;
define the complementary roles of different imaging modalities in hypertrophic cardiomyopathy;
assess symptoms of patients with hypertrophic cardiomyopathy; and
perform periodic stratification of sudden cardiac death risk and recognize indications of referral for implantable cardiac defibrillator consideration.

Disclosure(s):

Arnon Adler: BMS: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Patrick Garceau, MD, FRCPC: No financial relationships to disclose

Kevin Ong, MD, FRCPC, FACC, FASE: Bristol Myers Squibb: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing)

Marc Ruel, MD, MPH: No financial relationships to disclose

Chair(s)

MW

Michael R. Ward, MD, PhD, FRCPC

Clinical Fellow, Interventional Cardiology
University Of Toronto

Panelist(s)

AA

Arnon Adler

Staff cardiologist
University Health Network
LA

Laura T. Arbour, MD FRCPC FCCMG (she/her/hers)

Medical Geneticist
University of British Columbia
University of British Columbia
Patrick Garceau, MD, FRCPC

Cardiologist
Institut de Cardiologie de Montréal
Université de Montréal
Kevin Ong, MD, FRCPC, FACC, FASE

Clinical Assistant Professor
Division of Cardiology, University of British Columbia
St. Paul's Hospital, University of British Columbia
Marc Ruel, MD, MPH

Professor and MICS Chair, Cardiac Surgery
University of Ottawa
University of Ottawa Heart Institute
CS

Colette Seifer, MB, FRCP

Cardiologist
University of Manitoba/St Boniface Hospital
University of Manitoba

Planning Committee Member(s)

AC

Andrew Crean, MRCP, FRCR

Professor of Medicine
N/A
RT

Rafik Tadros, MD, PhD

Cardiac Electrophysiologist
CHRS
CHRS